
Trials found the drug could delay disease progression by 12.5 months on average
(Picture: PA Media)A drug that can hold off prostate cancer for a year has been approved by health authorities in the UK.
The Medicines and Healthcare products Regulatory Agency (MHRA) has ruled in favour of Pluvicto, which could delay the progression of the disease by more than a year, the Independent reports.